Bone Therapeutics announced it has treated the first patient for the ALLOB Phase IIb clinical study in patients with difficult-to-heal tibial fractures. The successful completion of Bone Therapeutics’ ALLOB trials would further demonstrate the promise of mesenchymal stromal derived cell therapies for the treatment of other underserved conditions.
[Bone Therapeutics]
0